Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients

Sponsor
University of Leipzig
Study ID
NCT05237713
Phase
PHASE2
Status
Terminated

Conditions

  • Anemia
  • Myelodysplastic Syndromes

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Canakinumab Injection — DRUG
    Administration for a duration of 6 months for all patients and in case of response further treatment for up to three years

Study Details

Hematologic improvement of erythrocytes after 6 months of canakinumab treatment.

Key Dates

Start date
Apr 26, 2022
Status verified
May 2024
Primary completion
Feb 29, 2024
Completion
Feb 29, 2024

Study Design

Enrollment
10 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Canakinumab treatment
    200 mg canakinumab subcutaneously every three weeks

Primary Outcome Measure

HI-E after 6 months of treatment [ Time Frame: 6 months ]

Related Studies